Products
Online Inquiry
MJN110
Cat. No.:
OB0225WX-1875
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
MJN110 is a potent MAGL inhibitor with an IC50 of 9.1 nM, known for its high selectivity and ability to modulate lipid signaling pathways.
Synonym:
Cravatt Reagent; 1438416-21-7; MJN-110; 2,5-dioxopyrrolidin-1-yl 4-(bis(4-chlorophenyl)methyl)piperazine-1-carboxylate; (2,5-dioxopyrrolidin-1-yl) 4-[bis(4-chlorophenyl)methyl]piperazine-1-carboxylate; 4-[bis(4-chlorophenyl)methyl]-1-piperazinecarboxylic acid, 2,5-dioxo-1-pyrrolidinyl ester; 4-[Bis-(4-chloro-phenyl)-methyl]-piperazine-1-carboxylic acid N-hydroxysuccinimide ester
CAS No.:
1438416-21-7
Compound CID:
71722059
Formula:
C22H21Cl2N3O4
Formula Weight:
462.33
Specification
Targets&IC50:
MAGL: 9.1 nM
Relative Density:
1.47 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
MJN110 is utilized in neuroscience research as a highly potent and selective MAGL inhibitor to study the suppression of pro-inflammatory eicosanoids and its neuroprotective effects in brain injury models.
Library Information
Target:
Lipase
Receptor:
MAGL
Pathways:
Metabolism
Plate Number:
AOCL-25
Plate Location:
a6
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
27.5 mg/mL; 59.48 mM
